Aberrant expression of miR‑153 is associated with the poor prognosis of cervical cancer

Liu,Li; Lai,Xiaojing; Yuan,Changjin; Lv,Xiuwei; Yu,Tao; He,Wenyu; Liu,Jiaoping; Zhang,Haiming

doi:10.3892/ol.2018.8475

Aberrant expression of miR‑153 is associated with the poor prognosis of cervical cancer

Authors:
- Li Liu
- Xiaojing Lai
- Changjin Yuan
- Xiuwei Lv
- Tao Yu
- Wenyu He
- Jiaoping Liu
- Haiming Zhang
View Affiliations

Affiliations: Department of Oncology, Integrated Traditional Chinese and Western Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430012, P.R. China, Applied Biotechnology Research Center, Hubei Engineering Research Center of Viral Vector, Wuhan Institute of Bioengineering, Economic Development Zone of Yangluo, Wuhan, Hubei 430415, P.R. China
Published online on: April 12, 2018 https://doi.org/10.3892/ol.2018.8475
Pages: 9183-9187
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated that microRNAs (miRNAs) are frequently dysregulated in tumors and are associated with the initiation and progression of various types of cancer. miR‑153 has been previously shown to have an anti‑tumor effect in the majority of cancer types. However, to date, the expression status and function of miR‑153 in cervical cancer (CC) remains unclear. In the present study, the expression of miR‑153 in CC tissues and cell lines was examined, revealing that the expression of miR‑153 was markedly downregulated in the CC tissues and cell lines investigated, when compared with matched noncancerous tissues and normal cervical epithelial cell line. Furthermore, ectopic expression of miR‑153 by miR‑153 mimic inhibited cell proliferation; however, transfection with the miR‑153 inhibitor promoted the cell proliferation in CC cell lines. Finally, the results showed that the downregulation of miR‑153 was associated with poor 5‑year over survival in CC patients and it could be regarded as an independent biomarker to predict the prognosis of CC patients. Collectively, these results indicated that miR‑153 may function as a tumor suppressor in CC, and it may be a potential novel therapeutic target for CC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Wang JM, Ju BH, Pan CJ, Gu Y, Li MQ, Sun L, Xu YY and Yin LR: MiR-214 inhibits cell migration, invasion and promotes the drug sensitivity in human cervical cancer by targeting FOXM1. Am J Transl Res. 9:3541–3557. 2017.PubMed/NCBI
4	Ellenson LH and Wu TC: Focus on endometrial and cervical cancer. Cancer Cell. 5:533–538. 2014. View Article : Google Scholar
5	Yoshikawa H: Progress in the World and challenges in Japan on HPV vaccination for cervical cancer prevention. Gan To Kagaku Ryoho. 37:971–975. 2010.(In Japanese). PubMed/NCBI
6	Ghebre RG, Grover S, Xu MJ, Chuang LT and Simonds H: Cervical cancer control in HIV-infected women: Past, present and future. Gynecol Oncol Rep. 21:101–108. 2017. View Article : Google Scholar : PubMed/NCBI
7	Calin GA and Croce CM: MicroRNA-cancer connection: The beginning of a new tale. Cancer Res. 66:7390–7394. 2006. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak Rh, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
11	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 9:8522017. View Article : Google Scholar : PubMed/NCBI
12	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
13	Kozomara A and Griffths-Jones S: miRBase: Annotating high confdence microRNAs using deep sequencing data. Nucleic Acids Res. 42:D68–D73. 2014. View Article : Google Scholar : PubMed/NCBI
14	Wu XW, Li L, Li Y and Liu ZH: MiR-153 promotes breast cancer cell apoptosis by targeting HECTD3. Am J Cancer Res. 6:1563–1571. 2016.PubMed/NCBI
15	Zhou J, Xie M, Shi Y, Luo B, Gong G, Li J, Wang J, Zhao W, Zi Y, Wu X and Wen J: MicroRNA-153 functions as a tumor suppressor by targeting SET6 and ZEB2 in ovarian cancer cells. Oncol Rep. 34:111–120. 2015. View Article : Google Scholar : PubMed/NCBI
16	Niu GF, Li B, Sun L and An CG: MicroRNA-153 inhibits osteosarcoma cells proliferation and invasion by targeting TGF-β2. PLoS One. 10:e01192252015. View Article : Google Scholar : PubMed/NCBI
17	Zuo J, Wang D, Shen H, Liu F, Han J and Zhang X: MicroRNA-153 inhibits tumor progression in esophageal squamous cell carcinoma by targeting SNAI1. Tumor Biol. 2016.(Epub ahead of print). View Article : Google Scholar
18	Wang Z and Liu C: MiR-153 regulates metastasis of gastric cancer through Snail1. Tumor Biol. 2015.(Epub ahead of print).
19	Liu F, Liu B, Qian J, Wu G, Li J and Ma Z: miR-153 enhances the therapeutic effect of gemcitabine by targeting SnaiI in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai). 49:520–529. 2017. View Article : Google Scholar : PubMed/NCBI
20	Shan N, Shen L, Wang J, He D and Duan C: MiR-153 inhibits migration and invasion of human non-small-cell lung cancer by targeting ADAM19. Biochem Biophys Res Commun. 456:385–391. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, Kelly G, Paraskeva C, Strefford J, Primrose J, et al: miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res. 73:6345–6347. 2013.
22	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
23	Chen ZL, Zhao XH, Wang JW, Li BZ, Wang Z, Sun J, Tan FW, Ding DP, Xu XH, Zhou F, et al: microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem. 286:10725–10734. 2011. View Article : Google Scholar : PubMed/NCBI
24	Wongfieng W, Jumnainsong A, Chamgramol Y, Sripa B and Leelayuwat C: 5′-UTR and 3′-UTR regulation of MICB expression in human cancer cells by novel microRNAs. Gene (Basel). 8:E2132017. View Article : Google Scholar
25	Biegel JM, Henderson E, Cox EM, Bonenfant G, Netzband R, Kahn S, Eager R and Pager CT: Cellular DEAD-box RNA helicase DDX6 modulates interaction of miR-122 with the 5′ untranslated region of hepatitis C virus RNA. Virology. 507:231–241. 2017. View Article : Google Scholar : PubMed/NCBI
26	Xiao Y, Li X, Wang H, Wen R, He J and Tang J: Epigenetic regulation of miR-129-2 and its effects on the proliferation and invasion in lung cancer cells. J Cell Mol Med. 19:2172–2180. 2015.PubMed/NCBI
27	Gregory RI and Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res. 65:3509–3512. 2005. View Article : Google Scholar : PubMed/NCBI
28	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
29	Xu L, Xu Q, Li X and Zhang X: MicroRNA-21 regulates the proliferation and apoptosis of cervical cancer cells via tumor necrosis factor-α. Mol Med Rep. 16:4659–4663. 2017. View Article : Google Scholar : PubMed/NCBI
30	Feng Y, Zou W, Hu C, Li G, Zhou S, He Y, Ma F, Deng C and Sun L: Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin. Arch Biochem Biophys. 623–624:20–30. 2017. View Article : Google Scholar
31	Du G, Gao D and Meng L: miR-21 inhibitor suppresses cell proliferation and colony formation regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells. Mol Med Rep. 15:2713–2719. 2017. View Article : Google Scholar : PubMed/NCBI
32	Su K, Wang CF, Zhang Y, Cai YJ, Zhang YY and Zhao Q: miR-940 upregulation contributes to human cervical cancer progression through p27 and PTEN inhibition. Int J Oncol. 2017.(Epub ahead of print). View Article : Google Scholar
33	Wang H and Gao W: DJ-1 expression in cervical carcinoma and its effects on cell viability and apoptosis. Med Sci Monit. 22:2943–2949. 2016. View Article : Google Scholar : PubMed/NCBI